Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PRTC logo PRTC
Upturn stock ratingUpturn stock rating
PRTC logo

PureTech Health PLC (PRTC)

Upturn stock ratingUpturn stock rating
$18.79
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/18/2025: PRTC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Above Average Performance

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Analysis of Past Performance

Type Stock
Historic Profit -9.14%
Avg. Invested days 35
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 4.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/18/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 453.70M USD
Price to earnings Ratio -
1Y Target Price 53.25
Price to earnings Ratio -
1Y Target Price 53.25
Volume (30-day avg) 2719
Beta 0.95
52 Weeks Range 17.00 - 34.00
Updated Date 02/18/2025
52 Weeks Range 17.00 - 34.00
Updated Date 02/18/2025
Dividends yield (FY) -
Basic EPS (TTM) -3

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -23054.86%

Management Effectiveness

Return on Assets (TTM) -13.39%
Return on Equity (TTM) -22.07%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -38900442
Price to Sales(TTM) 969.45
Enterprise Value -38900442
Price to Sales(TTM) 969.45
Enterprise Value to Revenue 348.82
Enterprise Value to EBITDA -51.93
Shares Outstanding 23942100
Shares Floating 158597465
Shares Outstanding 23942100
Shares Floating 158597465
Percent Insiders -
Percent Institutions 1.57

AI Summary

PureTech Health PLC: A Comprehensive Overview

Company Profile

History and Background:

PureTech Health PLC (PRTC) is a clinical-stage biotherapeutics company focused on discovering and developing novel treatments for inflammatory, fibrotic, and cardiovascular diseases. Founded in 2010, the company has its headquarters in Boston, Massachusetts, with a research & development site in Cambridge, UK. PureTech operates through two segments:

  1. Late-stage clinical assets: This includes a portfolio of four clinical-stage product candidates: LYT-100 (an oral therapy for inflammatory and fibrotic diseases), LYT-200 (an oral therapy for autoimmune and inflammatory diseases), AKB-492 (a gene therapy for high-risk cardiovascular disease), and LYT-300 (a gene therapy for alpha-1 antitrypsin deficiency).
  2. Early-stage discovery and development programs: This segment includes a pipeline of preclinical programs focused on inflammatory and fibrotic diseases, immunology, and synthetic biology.

Core Business Areas:

  • Discovery and development of novel therapeutic drugs: PureTech focuses on developing oral therapies, gene therapies, and antibody-drug conjugates.
  • Collaboration with academic and industry partners: They leverage partnerships to accelerate research and development efforts.
  • Commercialization of approved drugs: Once a drug receives regulatory approval, PureTech partners with pharmaceutical companies for distribution and marketing.

Leadership Team and Corporate Structure:

  • Daphne Zohar: CEO, with extensive experience in the pharmaceutical industry, including Roche and Genentech.
  • Joseph Bolen, MD: Chief Medical Officer, previously held leadership roles at Pfizer and Amgen.
  • David A. Simpson: Chief Financial Officer, brings over 25 years of experience in finance and accounting.
  • Board of Directors: Comprised of industry veterans with expertise in drug development, finance, and venture capital.

Top Products and Market Share

  • LYT-100: An oral therapy for inflammatory bowel disease (IBD) targeting LFA-1, an integrin involved in both chronic and acute inflammation. Phase 3 trials are ongoing.
  • LYT-200: An oral therapy for moderate-to-severe psoriasis targeting IL-17A, a key cytokine in autoimmune diseases. Topline data from Phase 2a trial is expected in Q4 2023.
  • AKB-492: A gene therapy for patients with documented coronary or peripheral artery disease. Phase 1b/2a trial is ongoing.
  • LYT-300: A gene therapy for alpha-1 antitrypsin deficiency, a rare genetic disorder. Phase 1/2a trial is ongoing.

Market Share:

The company's current products are in development, hence they do not hold a market share in any specific therapeutic area. However, the market potential for LYT-100, LYT-200, AKB-492, and LYT-300 is significant.

  • The global market for IBD therapies is estimated to reach $14.2 billion by 2027.
  • The global market for psoriasis treatments is expected to reach $18.4 billion by 2027.
  • The global cardiovascular gene therapy market is projected to reach $1.4 billion by 2028.
  • The global market for alpha-1 antitrypsin deficiency treatments is estimated to reach $3.4 billion by 2027.

Competitive Landscape:

  • IBD: Major competitors include Pfizer (IBD portfolio), AbbVie (Humira), and Johnson & Johnson (Stelara).
  • Psoriasis: Major competitors include AbbVie (Skyrizi), Eli Lilly (Taltz), and Novartis (Cosentyx).
  • Gene therapy for cardiovascular diseases: Competitors include BioMarin Pharmaceutical (valoctocogene roxaparvovec) and uniQure (etranacogene dezaparvovec).
  • Alpha-1 antitrypsin deficiency: Major competitor is CSL Behring (Glassia).

Total Addressable Market (TAM)

PureTech Health's TAM is vast, encompassing the global markets for inflammatory diseases, fibrotic diseases, cardiovascular diseases, and alpha-1 antitrypsin deficiency. Combining the individual market sizes mentioned above, PureTech's potential TAM is estimated to be over $37 billion.

About PureTech Health PLC

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2020-11-16
CEO & Executive Director Dr. Bharatt M. Chowrira J.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 90
Full time employees 90

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​